EUCTR2007-002093-60-GB进行中（未招募）1 期
Single agent phase II study of Forodesine (BCX1777) in the treatment of cutaneous T-Cell Lymphoma - forodesine in CTC
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Males or non-pregnant females aged =18 years;
- •2. Histologically confirmed diagnosis of CTCL, including mycosis fungoides and/or sezary syndrome;
- •3. Subjects with CTCL stages IB, IIA, IIB, III or IVA who have persistent, progressive, or recurrent disease during or following treatment with at least three forms of systemic therapy, one of which must have been bexarotene, unless treatment with oral bexarotene was not tolerated or was medically contraindicated;
- •4. Anticipated life expectancy > 6 months;
- •5. Performance status of 0, 1, or 2 by ECOG;
- •6. Females of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of study treatment ;
- •7. Females of child bearing potential and sexually active males, if indicated, must be willing and able to use method(s) of contraception that are adequate to prevent or minimize the risk of pregnancy for the duration of the study; and,
- •8. Written informed consent to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •CTCL-related Exclusion Criteria
- •1. Proven or suspected extracutaneous visceral CTCL involvement (M1) (CTCL stage IVB) (note: presence of lymphadenopathy is permitted);
- •2. Previous treatment with forodesine;
- •3. ECOG performance status >2;
- •4. Concomitant use of any anti-cancer therapy or immune modifier;
- •5. Concomitant use of any investigational agent or device;
- •6. Concurrent treatment with any other anti-CTCL therapy, or radiation therapy. Topical corticosteroids (except classes 1 and 2 which are prohibited) or low dose oral corticosteroids (=10 mg/day prednisone or equivalent) will not be excluded, but if used, must be a stable dose and schedule during the four weeks immediately prior to study entry;
- •7. Use of previous therapies for CTCL within the timeframes specified below:
- •a. Phototherapy in the previous 30 days;
- •b. Electron beam therapy, photopheresis, systemic anticancer therapy, interferon therapy, or other investigational therapy in the previous 30 days;
- •c. Oral retinoid (including bexarotene) in the previous 30 days;
- •d. Alemtuzumab (Campath) or other monoclonal antibody within the previous 30 days
- •e. Vorinostat or other HDAC inhibitor within previous 30 days
- •f. Any investigational therapy within the previous 30 days;
- •Hepatic/Renal/Metaboli Exclusion Criteria
- •8. ALT or AST >3 times ULN or alkaline phosphatase >2 times ULN;
- •9. Calculated creatine clearance =50mL/min or serum creatine =1.8mg/dL;
- •10. Serum potassium <3.3mg/dL or >5.5mg/dL;
- •11. Evidence of clinically significant (uncontrolled) hypo- or hyperthyroidism;
- •Cardiovascular Exclusion Criteria
- •12. Recent (in past 6 months) medically significant cardiac event (i.e., myocardial infarction, cardiac surgery);
- •13. Presence of congestive heart failure (NYHA class IV) or angina (NYHA class IV) or presence of a medically significant dysrhythmia;
- •14. Presence of any of the following ECG findings:
- •a. Congenital long QT syndrome;
- •b. QTc interval >480 msec (Bazett’s correction);
- •15. Presence of uncontrolled hypertension manifested by systolic blood pressure =160mmHg and or diastolic blood pressure =90mmHg;
- •Hematologic Exclusion Criteria
- •16. Hemoglobin <9.0gm/dL (intermittent red blood cell transfusions permitted);
- •17. Absolute neutrophil count <1500cells/mm^3;
- •18. Platelet count <75,000/mm^3;
- •19. Requirement for neutrophil or platelet growth factor therapy or administration of such therapy in the previous 30 days;
- •20. CD4 count <200/mm^3
- •Infection-Related Exclusion Criteria
- •21. Documented current active infection with HIV, Hepatitis B, Hepatitis C and/or CMV;
- •22. Presence of uncontrolled bacterial or viral infection (subject may be receiving chronic antimicrobial therapy); or,
- •23. History of culture-documented bacteremia in the previous 2 weeks.
- •General Exclusion Criteria
- •24. Recent (i.e., in past 2 weeks) change in doses or regimens of medications u
研究者
相似试验
进行中（未招募）
不适用
Single agent phase II study of Forodesine (BCX1777) in the treatment of cutaneous T-Cell Lymphoma - forodesine in CTCEUCTR2007-002093-60-ATBioCryst Pharmaceuticals, Inc.150
进行中（未招募）
1 期
Single agent phase II study of Forodesine (BCX1777) in the treatment of cutaneous T-Cell Lymphoma - forodesine in CTCEUCTR2007-002093-60-FRBioCryst Pharmaceuticals, Inc.
进行中（未招募）
不适用
Single agent phase II study of Forodesine (BCX1777) in the treatment of cutaneous T-Cell Lymphoma - forodesine in CTCEUCTR2007-002093-60-FIBioCryst Pharmaceuticals, Inc.150
进行中（未招募）
不适用
Single agent phase II study of Forodesine (BCX1777) in the treatment of cutaneous T-Cell Lymphoma - forodesine in CTCEUCTR2007-002093-60-DEBioCryst Pharmaceuticals, Inc.150
进行中（未招募）
不适用
Single agent phase II study of Forodesine (BCX1777) in the treatment of cutaneous T-Cell Lymphoma - forodesine in CTCPrimary cutaneous T-cell lymphomas (CTCLs)MedDRA version: 9.1Level: LLTClassification code 10028508Term: Mycosis fungoides/Sezary syndromeEUCTR2007-002093-60-DKBioCryst Pharmaceuticals, Inc.150